Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

Reference intervals for blood-based biochemical analytes of southern Beaufort Sea polar bears.

Fry TL, Friedrichs KR, Atwood TC, Duncan C, Simac K, Goldberg T.

Conserv Physiol. 2019 Sep 16;7(1):coz040. doi: 10.1093/conphys/coz040. eCollection 2019.

2.

Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy.

Shah NN, Qin H, Yates B, Su L, Shalabi H, Raffeld M, Ahlman MA, Stetler-Stevenson M, Yuan C, Guo S, Liu S, Hughes SH, Fry TJ, Wu X.

Blood Adv. 2019 Aug 13;3(15):2317-2322. doi: 10.1182/bloodadvances.2019000219. No abstract available.

3.

Introduction: Immunological Reviews volume 290.

Fry TJ.

Immunol Rev. 2019 Jul;290(1):4-5. doi: 10.1111/imr.12797. No abstract available.

PMID:
31355490
4.

Multi-Specific CAR Targeting to Prevent Antigen Escape.

Walsh Z, Ross S, Fry TJ.

Curr Hematol Malig Rep. 2019 Oct;14(5):451-459. doi: 10.1007/s11899-019-00537-5. Review.

PMID:
31332617
5.

Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.

Panch SR, Srivastava SK, Elavia N, McManus A, Liu S, Jin P, Highfill SL, Li X, Dagur P, Kochenderfer JN, Fry TJ, Mackall CL, Lee D, Shah NN, Stroncek DF.

Mol Ther. 2019 Jul 3;27(7):1275-1285. doi: 10.1016/j.ymthe.2019.05.015. Epub 2019 May 30.

PMID:
31178392
6.

Introduction by the Guest Editor, Terry J. Fry.

Fry TJ.

Cancer J. 2019 May/Jun;25(3):178. doi: 10.1097/PPO.0000000000000382. No abstract available.

PMID:
31135524
7.

Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.

Ramakrishna S, Highfill SL, Walsh Z, Nguyen SM, Lei H, Shern JF, Qin H, Kraft IL, Stetler-Stevenson M, Yuan CM, Hwang JD, Feng Y, Zhu Z, Dimitrov D, Shah NN, Fry TJ.

Clin Cancer Res. 2019 Sep 1;25(17):5329-5341. doi: 10.1158/1078-0432.CCR-18-3784. Epub 2019 May 20.

PMID:
31110075
8.

Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells.

Qin H, Edwards JP, Zaritskaya L, Gupta A, Mu CJ, Fry TJ, Hilbert DM, LaFleur DW.

Mol Ther. 2019 Jul 3;27(7):1262-1274. doi: 10.1016/j.ymthe.2019.04.010. Epub 2019 Apr 17.

PMID:
31043341
9.

Mechanisms of resistance to CAR T cell therapy.

Shah NN, Fry TJ.

Nat Rev Clin Oncol. 2019 Jun;16(6):372-385. doi: 10.1038/s41571-019-0184-6. Review.

PMID:
30837712
10.

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.

Yamamoto TN, Lee PH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, Eidizadeh A, Eil R, Fioravanti J, Gattinoni L, Kochenderfer JN, Fry TJ, Aksoy BA, Hammerbacher JE, Cruz AC, Siegel RM, Restifo NP, Klebanoff CA.

J Clin Invest. 2019 Feb 25;129(4):1551-1565. doi: 10.1172/JCI121491. eCollection 2019 Feb 25.

11.

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.

Qin H, Ramakrishna S, Nguyen S, Fountaine TJ, Ponduri A, Stetler-Stevenson M, Yuan CM, Haso W, Shern JF, Shah NN, Fry TJ.

Mol Ther Oncolytics. 2018 Nov 6;11:127-137. doi: 10.1016/j.omto.2018.10.006. eCollection 2018 Dec 21.

12.

Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution.

Melendez-Munoz R, Marchalik R, Jerussi T, Dimitrova D, Nussenblatt V, Beri A, Rai K, Wilder JS, Barrett AJ, Battiwalla M, Childs RW, Fitzhugh CD, Fowler DH, Fry TJ, Gress RE, Hsieh MM, Ito S, Kang EM, Pavletic SZ, Shah NN, Tisdale JF, Gea-Banacloche J, Kanakry CG, Kanakry JA.

Biol Blood Marrow Transplant. 2019 Mar;25(3):577-586. doi: 10.1016/j.bbmt.2018.10.011. Epub 2018 Oct 18.

PMID:
30342913
13.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ.

Nat Med. 2018 Oct;24(10):1499-1503. doi: 10.1038/s41591-018-0201-9. Epub 2018 Oct 1.

14.

Murine pre-B-cell ALL induces T-cell dysfunction not fully reversed by introduction of a chimeric antigen receptor.

Qin H, Ishii K, Nguyen S, Su PP, Burk CR, Kim BH, Duncan BB, Tarun S, Shah NN, Kohler ME, Fry TJ.

Blood. 2018 Nov 1;132(18):1899-1910. doi: 10.1182/blood-2017-12-815548. Epub 2018 Sep 12.

15.

Chimeric Antigen Receptor T-Cell Therapy.

Ogba N, Arwood NM, Bartlett NL, Bloom M, Brown P, Brown C, Budde EL, Carlson R, Farnia S, Fry TJ, Garber M, Gardner RA, Gurschick L, Kropf P, Reitan JJ, Sauter C, Shah B, Shpall EJ, Rosen ST.

J Natl Compr Canc Netw. 2018 Sep;16(9):1092-1106. doi: 10.6004/jnccn.2018.0073.

PMID:
30181421
16.

Systematic Review of Quality Improvement Initiatives Related to Cue-Based Feeding in Preterm Infants.

Fry TJ, Marfurt S, Wengier S.

Nurs Womens Health. 2018 Oct;22(5):401-410. doi: 10.1016/j.nwh.2018.07.006. Epub 2018 Aug 21. Review.

PMID:
30138603
17.

Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.

Shalabi H, Wolters PL, Martin S, Toledo-Tamula MA, Roderick MC, Struemph K, Kane E, Yates B, Delbrook C, Mackall CL, Lee DW, Fry TJ, Shah NN.

J Immunother. 2018 Sep;41(7):350-358. doi: 10.1097/CJI.0000000000000241.

18.

Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression.

Jacobsohn DA, Loken MR, Fei M, Adams A, Brodersen LE, Logan BR, Ahn KW, Shaw BE, Kletzel M, Olszewski M, Khan S, Meshinchi S, Keating A, Harris A, Teira P, Duerst RE, Margossian SP, Martin PL, Petrovic A, Dvorak CC, Nemecek ER, Boyer MW, Chen AR, Davis JH, Shenoy S, Savasan S, Hudspeth MP, Adams RH, Lewis VA, Kheradpour A, Kasow KA, Gillio AP, Haight AE, Bhatia M, Bambach BJ, Haines HL, Quigg TC, Greiner RJ, Talano JM, Delgado DC, Cheerva A, Gowda M, Ahuja S, Ozkaynak M, Mitchell D, Schultz KR, Fry TJ, Loeb DM, Pulsipher MA.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2040-2046. doi: 10.1016/j.bbmt.2018.06.010. Epub 2018 Jun 19.

19.

Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma.

Shalabi H, Kraft IL, Wang HW, Yuan CM, Yates B, Delbrook C, Zimbelman JD, Giller R, Stetler-Stevenson M, Jaffe ES, Lee DW, Shern JF, Fry TJ, Shah NN.

Haematologica. 2018 May;103(5):e215-e218. doi: 10.3324/haematol.2017.183459. Epub 2018 Feb 1. No abstract available.

20.

Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathways.

Gough SM, Goldberg L, Pineda M, Walker RL, Zhu YJ, Bilke S, Chung YJ, Dufraine J, Kundu S, Jacoby E, Fry TJ, Fischer S, Panzer-Grümayer R, Meltzer PS, Aplan PD.

Blood Adv. 2017 Sep 8;1(20):1749-1759. doi: 10.1182/bloodadvances.2017009837. eCollection 2017 Sep 12.

21.

TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance.

Yang Y, Kohler ME, Chien CD, Sauter CT, Jacoby E, Yan C, Hu Y, Wanhainen K, Qin H, Fry TJ.

Sci Transl Med. 2017 Nov 22;9(417). pii: eaag1209. doi: 10.1126/scitranslmed.aag1209.

PMID:
29167392
22.

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL.

Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.

23.

Anti-CD19 resistance can "stem" from progenitors.

Shah NN, Fry TJ.

Blood. 2017 Nov 2;130(18):1961-1963. doi: 10.1182/blood-2017-09-804070. No abstract available.

24.

Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.

Cornetta K, Duffy L, Turtle CJ, Jensen M, Forman S, Binder-Scholl G, Fry T, Chew A, Maloney DG, June CH.

Mol Ther. 2018 Jan 3;26(1):280-288. doi: 10.1016/j.ymthe.2017.09.008. Epub 2017 Sep 12.

25.

Myeloablative hematopoietic stem cell transplantation improves survival but is not curative in a pre-clinical model of myelodysplastic syndrome.

Chung YJ, Fry TJ, Aplan PD.

PLoS One. 2017 Sep 27;12(9):e0185219. doi: 10.1371/journal.pone.0185219. eCollection 2017.

26.

Shooter-System Performance Variability as a Function of Recoil Dynamics.

Morelli F, Neugebauer JM, Haynes CA, Fry TC, Ortega SV, Struve DJ, LaFiandra ME, Larkin GB.

Hum Factors. 2017 Sep;59(6):973-985. doi: 10.1177/0018720817700537. Epub 2017 Mar 15.

PMID:
28796972
27.

Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

Walker AJ, Majzner RG, Zhang L, Wanhainen K, Long AH, Nguyen SM, Lopomo P, Vigny M, Fry TJ, Orentas RJ, Mackall CL.

Mol Ther. 2017 Sep 6;25(9):2189-2201. doi: 10.1016/j.ymthe.2017.06.008. Epub 2017 Jul 1.

28.

Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.

Stroncek DF, Lee DW, Ren J, Sabatino M, Highfill S, Khuu H, Shah NN, Kaplan RN, Fry TJ, Mackall CL.

J Transl Med. 2017 Mar 16;15(1):59. doi: 10.1186/s12967-017-1160-5.

29.

Autologous lymphapheresis for the production of chimeric antigen receptor T cells.

Allen ES, Stroncek DF, Ren J, Eder AF, West KA, Fry TJ, Lee DW, Mackall CL, Conry-Cantilena C.

Transfusion. 2017 May;57(5):1133-1141. doi: 10.1111/trf.14003. Epub 2017 Feb 24.

30.

Procalcitonin and cytokine profiles in engraftment syndrome in pediatric stem cell transplantation.

Shah NN, Watson TM, Yates B, Liewehr DJ, Steinberg SM, Jacobsohn D, Fry TJ.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26273. Epub 2016 Oct 20.

PMID:
27762068
31.

Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.

Shah NN, Loeb DM, Khuu H, Stroncek D, Ariyo T, Raffeld M, Delbrook C, Mackall CL, Wayne AS, Fry TJ.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2149-2154. doi: 10.1016/j.bbmt.2016.08.028. Epub 2016 Sep 12.

32.

The functional interplay between systemic cancer and the hematopoietic stem cell niche.

Giles AJ, Chien CD, Reid CM, Fry TJ, Park DM, Kaplan RN, Gilbert MR.

Pharmacol Ther. 2016 Dec;168:53-60. doi: 10.1016/j.pharmthera.2016.09.006. Epub 2016 Sep 2. Review.

33.

Weighing up the evidence.

Fry T, Wall A.

J Fam Health. 2016 Sep;26(5):11-12. No abstract available.

PMID:
29727090
34.

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.

Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, Qin H, Yang Y, Chien CD, Seif AE, Lei H, Song YK, Khan J, Lee DW, Mackall CL, Gardner RA, Jensen MC, Shern JF, Fry TJ.

Nat Commun. 2016 Jul 27;7:12320. doi: 10.1038/ncomms12320.

35.

Less talk, more action.

Fry T.

J Fam Health. 2016 Mar-Apr;26(2):27-8. No abstract available.

PMID:
27263190
36.

Extinct Beringian wolf morphotype found in the continental U.S. has implications for wolf migration and evolution.

Meachen JA, Brannick AL, Fry TJ.

Ecol Evol. 2016 Apr 24;6(10):3430-8. doi: 10.1002/ece3.2141. eCollection 2016 May.

37.

Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.

Sabatino M, Hu J, Sommariva M, Gautam S, Fellowes V, Hocker JD, Dougherty S, Qin H, Klebanoff CA, Fry TJ, Gress RE, Kochenderfer JN, Stroncek DF, Ji Y, Gattinoni L.

Blood. 2016 Jul 28;128(4):519-28. doi: 10.1182/blood-2015-11-683847. Epub 2016 May 25.

38.

The NCMP--time to extend, or call a halt?

Fry T, Wall A.

J Fam Health. 2016 Jan-Feb;26(1):38-9. No abstract available.

PMID:
26999907
39.

Research involving pediatric stem cell donors: A way forward.

Wendler D, Shah NN, Pulsipher MA, Fry T, Grady C.

Clin Trials. 2016 Jun;13(3):304-10. doi: 10.1177/1740774515627156. Epub 2016 Feb 17.

40.

Childhood obesity--the eleventh hour.

Fry T.

J Fam Health. 2015 Nov-Dec;25(6):32-3. No abstract available.

PMID:
26749936
41.

Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.

Jacoby E, Yang Y, Qin H, Chien CD, Kochenderfer JN, Fry TJ.

Blood. 2016 Mar 10;127(10):1361-70. doi: 10.1182/blood-2015-08-664250. Epub 2015 Dec 11.

42.

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A.

Cancer Discov. 2015 Dec;5(12):1282-95. doi: 10.1158/2159-8290.CD-15-1020. Epub 2015 Oct 29.

43.

Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia.

Shalabi H, Angiolillo A, Fry TJ.

Front Pediatr. 2015 Oct 1;3:80. doi: 10.3389/fped.2015.00080. eCollection 2015. Review.

44.

Challenges and opportunities of allogeneic donor-derived CAR T cells.

Yang Y, Jacoby E, Fry TJ.

Curr Opin Hematol. 2015 Nov;22(6):509-515. doi: 10.1097/MOH.0000000000000181. Review.

45.

Respiratory Therapist Job Perceptions: The Impact of Protocol Use.

Metcalf AY, Stoller JK, Habermann M, Fry TD.

Respir Care. 2015 Nov;60(11):1556-9. doi: 10.4187/respcare.04156. Epub 2015 Aug 25.

46.

A robust in vivo model for B cell precursor acute lymphoblastic leukemia.

Fry TJ, Aplan PD.

J Clin Invest. 2015 Sep;125(9):3427-9. doi: 10.1172/JCI83799. Epub 2015 Aug 24. Review.

47.

Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

Qin H, Cho M, Haso W, Zhang L, Tasian SK, Oo HZ, Negri GL, Lin Y, Zou J, Mallon BS, Maude S, Teachey DT, Barrett DM, Orentas RJ, Daugaard M, Sorensen PH, Grupp SA, Fry TJ.

Blood. 2015 Jul 30;126(5):629-39. doi: 10.1182/blood-2014-11-612903. Epub 2015 Jun 3. Erratum in: Blood. 2016 Sep 8;128(10):1441.

48.

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.

Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL.

Nat Med. 2015 Jun;21(6):581-90. doi: 10.1038/nm.3838. Epub 2015 May 4.

49.

Patterns and factors associated with respiratory care protocol use.

Metcalf AY, Stoller JK, Fry TD, Habermann M.

Respir Care. 2015 May;60(5):636-43. doi: 10.4187/respcare.03699. Epub 2015 Jan 27.

50.

Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.

Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, Lemberg K, Hurley CK, Kleiner DE, Merchant MS, Pittaluga S, Sabatino M, Stroncek DF, Wayne AS, Zhang H, Fry TJ, Mackall CL.

Blood. 2015 Jan 29;125(5):784-92. doi: 10.1182/blood-2014-07-592881. Epub 2014 Dec 1.

Supplemental Content

Support Center